Catherine Wood's NTLA Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 16.88 M shares of Intellia Therapeutics, Inc. (NTLA) worth $285.54 M, representing 1.85% of the portfolio. First purchased in 2016-Q4, this long-term strategic position has been held for 39 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in NTLA, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 2.37 M shares. Largest reduction occurred in Q2 2021, reducing 1.93 M shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's Intellia Therapeutics (NTLA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Intellia Therapeutics (NTLA) Trades by Catherine Wood
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +2.37 M | Add 16.31% | 16.88 M | $16.92 |
| Q1 2026 | +301,923 | Add 2.13% | 14.51 M | $12.82 |
| Q4 2025 | +2.29 M | Add 19.20% | 14.21 M | $8.99 |
| Q3 2025 | -1.1 M | Reduce 8.44% | 11.92 M | $17.27 |
| Q2 2025 | +6,861 | Add 0.05% | 13.02 M | $9.38 |
| Q1 2025 | +474,629 | Add 3.79% | 13.01 M | $7.11 |
| Q4 2024 | +280,946 | Add 2.29% | 12.54 M | $11.66 |
| Q3 2024 | +659,651 | Add 5.69% | 12.26 M | $20.55 |
| Q2 2024 | +606,507 | Add 5.52% | 11.6 M | $22.38 |
| Q1 2024 | -423,167 | Reduce 3.71% | 10.99 M | $27.51 |
| Q4 2023 | +1.46 M | Add 14.71% | 11.41 M | $30.49 |
| Q3 2023 | +422,698 | Add 4.44% | 9.95 M | $31.62 |
| Q2 2023 | -311,235 | Reduce 3.16% | 9.53 M | $40.78 |
| Q1 2023 | +416,384 | Add 4.42% | 9.84 M | $37.27 |
| Q4 2022 | -236,270 | Reduce 2.45% | 9.42 M | $34.89 |
| Q3 2022 | +142,472 | Add 1.50% | 9.66 M | $55.96 |
| Q2 2022 | +533,551 | Add 5.94% | 9.51 M | $46.14 |
| Q1 2022 | +1.06 M | Add 13.44% | 8.98 M | $72.67 |
| Q4 2021 | +1.17 M | Add 17.40% | 7.92 M | $118.24 |
| Q3 2021 | -940,885 | Reduce 12.24% | 6.74 M | $134.15 |
| Q2 2021 | -1.93 M | Reduce 20.05% | 7.68 M | $161.91 |
| Q1 2021 | -1.58 M | Reduce 14.12% | 9.61 M | $80.26 |
| Q4 2020 | -213,082 | Reduce 1.87% | 11.19 M | $54.40 |
| Q3 2020 | +1,373 | Add 0.01% | 11.4 M | $19.88 |
| Q2 2020 | +1.16 M | Add 11.37% | 11.4 M | $21.02 |
| Q1 2020 | +1.5 M | Add 17.14% | 10.24 M | $12.23 |
| Q4 2019 | +270,856 | Add 3.20% | 8.74 M | $14.67 |
| Q3 2019 | +227,411 | Add 2.76% | 8.47 M | $13.35 |
| Q2 2019 | +261,967 | Add 3.28% | 8.24 M | $16.37 |
| Q1 2019 | +1.18 M | Add 17.34% | 7.98 M | $17.08 |
| Q4 2018 | +1.05 M | Add 18.22% | 6.8 M | $13.65 |
| Q3 2018 | +1.24 M | Add 27.48% | 5.75 M | $28.62 |
| Q2 2018 | +910,608 | Add 25.27% | 4.51 M | $27.36 |
| Q1 2018 | +2.23 M | Add 162.01% | 3.6 M | $21.09 |
| Q4 2017 | +1.38 M | Add 0.00% | 1.38 M | $19.22 |
| Q2 2017 | +94,960 | Add 118.92% | 174,810 | $16.00 |
| Q1 2017 | +53,306 | Add 200.82% | 79,850 | $14.09 |
| Q4 2016 | +26,544 | Add 0.00% | 26,544 | $13.11 |
Catherine Wood's Intellia Therapeutics Investment FAQs
Catherine Wood first purchased Intellia Therapeutics, Inc. (NTLA) in Q4 2016, acquiring 26,544 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held Intellia Therapeutics, Inc. (NTLA) for 39 quarters since Q4 2016.
Catherine Wood's largest addition to Intellia Therapeutics, Inc. (NTLA) was in Q2 2026, adding 16,875,684 shares worth $285.54 M.
According to the latest 13F filing for Q2 2026, Catherine Wood's firm, Ark Investment Management LLC, owns 16,875,684 shares of Intellia Therapeutics, Inc. (NTLA), valued at approximately $285.54 M.
As of the Q2 2026 filing, Intellia Therapeutics, Inc. (NTLA) represents approximately 1.85% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.
Catherine Wood's peak holding in Intellia Therapeutics, Inc. (NTLA) was 16,875,684 shares, as reported at the end of Q2 2026.